|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquired_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:advocacy
|
engagement with communities
|
|
gptkbp:biotechnology_innovation
|
gene editing technologies
|
|
gptkbp:biotechnology_sector
|
innovative therapies
|
|
gptkbp:ceo
|
Asher Cohen
|
|
gptkbp:clinical_trial
|
patient safety
volunteers
biomarkers
multiple locations
Phase 2
safety and efficacy
efficacy studies
published data
adaptive trials
Phase 1/2
quality of life measures
NCT04023901
NCT04522612
|
|
gptkbp:collaboration
|
AAV gene therapy
|
|
gptkbp:collaborations
|
biopharmaceutical companies
academic partnerships
|
|
gptkbp:focus
|
gptkb:gene_therapy
|
|
gptkbp:focuses_on
|
gptkb:gene_therapy
|
|
gptkbp:founded
|
gptkb:2017
|
|
gptkbp:founder
|
Asher Cohen
|
|
gptkbp:funding
|
gptkb:venture_capital
government grants
private funding
|
|
gptkbp:future_goals
|
expand therapeutic pipeline.
|
|
gptkbp:goal
|
disease modification
|
|
gptkbp:has_advisory_board
|
experts in gene therapy
|
|
gptkbp:headquarters
|
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Prevail Therapeutics
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:instruction_set
|
multiple product candidates
|
|
gptkbp:invention
|
gene therapy technologies
|
|
gptkbp:investment
|
$100 million
institutional investors
|
|
gptkbp:leadership
|
biotech industry veterans
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:mission
|
transform lives through gene therapy.
|
|
gptkbp:notable_products
|
PR001
PR006
|
|
gptkbp:partnership
|
gptkb:Duke_University
gptkb:University_of_Pennsylvania
research institutions
|
|
gptkbp:patient_population
|
neurodegenerative disease patients
|
|
gptkbp:publications
|
peer-reviewed journals
|
|
gptkbp:regulatory_compliance
|
FDA approved
FDA submissions
|
|
gptkbp:research
|
clinical trials
|
|
gptkbp:research_areas
|
neurology
gene delivery systems
|
|
gptkbp:research_focus
|
gptkb:neurodegenerative_diseases
rare diseases
|
|
gptkbp:specializes_in
|
gptkb:neurodegenerative_diseases
|
|
gptkbp:targets
|
gptkb:neurodegenerative_diseases
|
|
gptkbp:technology
|
AAV vector
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:type_of
|
gptkb:public_company
|
|
gptkbp:website
|
www.prevailtherapeutics.com
|